Investigating the antifibrotic effect of the antiparasitic drug Praziquantel in in vitro and in vivo preclinical models
Open Access
- 30 June 2020
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1), 1-12
- https://doi.org/10.1038/s41598-020-67514-4
Abstract
Tissue fibrosis underlies the majority of human mortality to date with close to half of all reported deaths having a fibrotic etiology. The progression of fibrosis is very complex and reputed irreversible once established. Although some preventive options are being reported, therapeutic options are still scarce and in very high demand, given the rise of diseases linked to fibroproliferative disorders. Our work explored four platforms, complementarily, in order to screen preventive and therapeutic potentials of the antiparasitic drug Praziquantel as a possible antifibrotic. We applied the mouse CCl4-driven liver fibrosis model, the mouse chronic schistosomiasis liver fibrosis model, as well as novel 2D and 3D human cell-based co-culture of human hepatocytes, KCs (Kupffer cells), LECs (Liver Endothelial Cells), HSCs (Hepatic Stellate Cells) and/or myofibroblasts to mimic in vivo fibrotic responses and dynamics. Praziquantel showed some effect on fibrosis marker when preventively administered before severe establishment of fibrosis. However, it failed to potently reverse already established fibrosis. Together, we provided a novel sophisticated multi-assay screening platform to test preventive and therapeutic antifibrotic candidates. We further demonstrated a direct preventive potential of Praziquantel against the onset of fibrosis and the confirmation of its lack of therapeutic potential in reversing already established fibrosis.Keywords
Funding Information
- Merck KGaA (100009945)
This publication has 75 references indexed in Scilit:
- Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADMEArchives of Toxicology, 2013
- Multi-cell type human liver microtissues for hepatotoxicity testingArchives of Toxicology, 2012
- Anti-inflammatory/anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against Schistosoma mansoni-induced liver fibrosisParasites & Vectors, 2012
- RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in RodentsJournal of Pharmacology and Experimental Therapeutics, 2012
- Diphenyl Difluoroketone: A Potent Chemotherapy Candidate for Human Hepatocellular CarcinomaPLOS ONE, 2011
- New Insight into the Antifibrotic Effects of Praziquantel on Mice in Infection with Schistosoma japonicumPLOS ONE, 2011
- Dynamics of hepatic stellate cells, collagen types I and III synthesis and gene expression of selected cytokines during hepatic fibrogenesis following Mesocestoides vogae (Cestoda) infection in miceInternational Journal for Parasitology, 2010
- Factors controlling the effect of praziquantel on liver fibrosis inSchistosoma mansoni-infected patientsFEMS Immunology & Medical Microbiology, 2010
- Effect of Chemotherapy with Praziquantel on the Production of Cytokines and Morbidity Associated with Schistosomiasis MansoniAntimicrobial Agents and Chemotherapy, 2008
- Active and latent collagenase activity during reversal of hepatic fibrosis in murine schistosomiasisHepatology, 1989